PRECISION PCI

Dr. Bruce Samuels is an interventional cardiologist on staff at Cedars-Sinai Medical Center (CSMC) in Los Angeles, California. Dr. Samuels completed his medical studies at Albert Einstein College of Medicine in New York before returning to Southern California to complete his residency and chief residency in Internal Medicine at Harbor-UCLA Medical Center. At CSMC, he trained in both general and interventional cardiology before joining the medical staff there. In addition to his clinical practice in coronary intervention, Dr. Samuels has actively participated in numerous interventional trials including IVUS guided therapy, coronary physiology and microvascular disease. He is also working closely with the Barbra Streisand Women’s Heart Center based at CSMC, working as an interventionalist in the active coronary reactivity research there. As co-chair of a 30-day readmissions task force, he has helped to shape policy for CSMC in its efforts to improve quality delivery of care. He has frequently been invited as faculty to many scientific meetings and is a sought after speaker for numerous peer educational platforms. Dr. Samuels is a fellow of the American College of Cardiology and is Board Certified in Internal Medicine, Cardiovascular Diseases, and Interventional Cardiology. He is married with three sons; his outside interests include contemporary art and long distance running.

Dr Justin Davies is a honorary 
interventional cardiologist at Hammersmith Hospital, Imperial College NHS Trust, London. After training at Imperial College, he won a prestigious BHF research fellowship to study arterial haemodynamics. Since then he has continued to
work on the development of mathematical algorithms to aid understanding of large artery physiology and to develop new tools to assess arterial disease. The holder of several patents,
he has published widely in the field of hypertension, coronary and large artery physiology and is the winner of many national and international awards. He has several international collaborations, and is the developer of iFR and the co-principal investigator of the ADVISE studies, the DEFINE-FLAIR, ORBITA and DEFINE-PCI studies. Justin also has an interest in renal denervation, and has lead the first-in-man studies to evaluate the safety of this technique to patients with chronic systolic heart failure (REACH studies).

Prof Andrew Sharp qualified from Edinburgh Medical School in 1998 and is Professor of Cardiology at the University Hospital of Wales and Cardiff University in the U.K. He conducted his early training at the Royal Infirmary of Edinburgh, before moving to London for his senior clinical training. He completed the prestigious Milan-Imperial Interventional Cardiology Fellowship programme, having spent a year in San Raffaele and Columbus Hospitals, Milan, Italy, under the tutelage of Professor Antonio Colombo. He also spent three years training in interventional cardiology at Imperial College Hospitals in London. Prof Sharp was awarded an MD postgraduate research degree from the University of Edinburgh for his work on the hypertensive heart and his research interests include intracoronary imaging and physiology. as well as the use of device-based treatments for hypertension and pulmonary embolism.

Gregg W. Stone, MD, FACC, MSCAI is an interventional cardiologist and Director of Academic Affairs for the Mount Sinai Heart Health System and Professor of Medicine (Cardiology) and Professor of Population Health Sciences and Policy at the Icahn School of Medicine at Mount Sinai in New York, NY. Dr. Stone has served as the national or international principal investigator for more than 120 national and international multicenter randomized trials (many of which have led to new device approval or indications in the US), has authored more than 2000 manuscripts and abstracts published in the peer-reviewed literature, and has delivered thousands of invited lectures around the world. With a 2018 H-factor of 152, Dr. Stone was recently listed in Nature Medicine as one of the most prolific authors in science. Dr. Stone's areas of expertise include interventional therapies of acute coronary syndromes, myocardial infarction and cardiogenic shock; drug-eluting stents and bioresorbable scaffolds; left main and complex coronary artery disease intervention; antiplatelet and antithrombotic pharmacotherapies; transcatheter valve repair and replacement; interventional hypertension and heart failure therapies; left atrial appendage closure; intravascular imaging (IVUS, OCT and NIRS); vulnerable plaque diagnosis and treatment; adjunctive interventional devices including atherectomy, distal embolic protection, thrombectomy, covered stents, chronic total occlusion devices, and brachytherapy; saphenous vein graft therapies; contrast nephropathy; clinical trial design; and regulatory issues. Dr. Stone is the director of TCT, the world's largest symposium devoted to interventional cardiology and vascular medicine. Dr. Stone founded the annual National Interventional Cardiology Fellow's Course and Transcatheter Valve Therapies TVT), the Chronic Total Occlusion (CTO) Summit, and co-directs multiple other meetings in the US, China, Russia, Europe, S. Korea and elsewhere.

Dr Sukhjinder Nijjer is a Consultant Cardiologist and Honorary Senior Clinical Lecturer at Imperial College London. He is the President of Cardiology at the Royal Society of Medicine and is the Communication Lead for the British Cardiovascular Intervention Society. He works at the Hammersmith Hospital as an Interventional Cardiologist and is an expert in Coronary Physiology. His PhD research focused on the development of instantaneous wave-free ratio (iFR) pullback and co-registration. He has published over 100 original academic papers and has involved in the DEFINE-FLAIR, SYNTAX-II and ORBITA-1 and ORBITA-2 research studies.

Dr Rasha Al-Lamee is an Interventional Cardiology Consultant at Imperial College Healthcare NHS Trust in London, UK. Dr Al-Lamee’s research interests are complex coronary intervention, coronary physiology and invasive intravascular assessment. She designed, conducted and led the ORBITA trial and is the lead author of the primary publication in The Lancet. At Imperial College, she is actively involved in the development and recruitment for a number of multi-centre clinical trials. Dr Al- Lamee has over 40 peer-reviewed publications and has presented at international Cardiology conferences worldwide throughout her clinical career. She studied at the University of Oxford and University College London. She went onto complete her training as a junior doctor on the Barts and the London Medical rotation before being appointed as a Specialist Registrar on the North West London Cardiology rotation in 2006. Dr Al-Lamee has twelve years of Cardiology experience and completed three years of Interventional Fellowship training at Hammersmith Hospital in London. She also spent a year training as an Interventional Fellow under the supervision of Professor Antonio Colombo in Milan. She completed specialist training in Cardiology in 2013.

Ron Waksman, MD, FACC, Associate Director, Division of Cardiology, MedStar Washington Hospital Center (MWHC) and Director of Cardiovascular Research and Advanced Education for the MedStar Heart and Vascular Institute at the MedStar Washington Hospital Center. With nearly 20 years of experience in leading edge medical technologies, Dr. Waksman is a world-renowned interventional cardiologist and is a highly sought after Principal Investigator for pre-clinical and clinical studies conducted in the United States and abroad. Dr Waksman has performed over 5000 coronary interventions throughout his career.

Dr Richard A. Shlofmitz, MD, FACC is the Chairman of Cardiology at St. Francis Hospital, The Heart Center®, in Roslyn, New York. A pioneer in interventional cardiology, Dr. Shlofmitz has worked to advance the field, with a focus on optimizing outcomes with the development of Precision PCI. He is a founding co-director of the annual Intravascular Imaging and Coronary Physiology Workshop. Performing over 1,000 coronary interventions annually, he has one of the largest volumes of experience in PCI. He has the most clinical experience with orbital atherectomy and OCT world-wide. His clinical research interests focus on optimizing coronary interventions and he serves on multiple scientific advisory boards and clinical trial steering committees to further this mission. Dr Shlofmitz has been one of the largest enrollers for multiple clinical trials, including TWILIGHT, ILUMIEN III, and Onyx, with more than 75 publications in peer-reviewed journals and was first to perform coronary intravascular lithotripsy (IVL) in North America as part of the DISRUPT CAD III trial.

Paul Teirstein, MD, is the Chief of Cardiology and Director of Interventional Cardiology for Scripps Clinic and Director of the Scripps Prebys Cardiovascular Institute for Scripps Health. With a primary focus on complex coronary interventions and new technology development, Dr. Teirstein has played an active role in the initial development and clinical investigation of coronary stent procedures, rotablator atherectomy, coronary angioscopy and the utilization of cardiopulmonary support. Dr. Teirstein pioneered the first effective treatment for restenosis (low dose radiation therapy) and was one of the early investigators of medicated and bioabsorbable stents. Recent areas of investigation include new technology for minimally invasive transcatheter aortic valve replacement (TAVR). Dr. Teirstein currently performs in excess of 800 stent procedures per year and maintains an active clinical research and teaching unit at Scripps Clinic where he strives to offer patients the most advanced cardiovascular care available worldwide.

Manesh Patel is the Chief of the Division of Cardiology and the Division of Clinical Pharmacology. His clinical interests include diagnostic and interventional coronary angiography, peripheral angiography and endovascular intervention. His is involved in several clinical trials involving patients with cardiovascular disease and in cardiac imaging. He is also the Chair of the American College of Cardiology Task Force for Appropriate Use Criteria for Cardiovascular Procedures and is Chair of the American Heart Association Diagnostic and Interventional Cath Committee. Patel's interest in cardiac imaging, quality of care, cardiac devices is also evident in his research. His integration of these efforts into his roles at Duke was recognized in 2010 when he received the prestigious Duke Cardiology Fellowship Mentor Award. In 2011, Dr. Patel was named the endowed John Bush Simpson Assistant Professor of Cardiology. In 2013, Dr. Patel received the Robert M. Califf Faculty clinical research Award. Currently, Dr. Patel is leading an effort to redesign the delivery of care to patients undergoing invasive catheterization procedures in the health system with a specific aim of measure and providing individualized, patient centered, innovative, and efficient care.

Allen Jeremias, MD, MSc, is the Director of Interventional Cardiology Research and Associate Director of the Cardiac Catheterization Laboratory at St. Francis Hospital in Roslyn, New York. He is also a member of the Cardiovascular Research Foundation in New York City where he currently serves as the Director of the Physiology Core Laboratory. He completed his medical training at The Cleveland Clinic Foundation, Stanford University School of Medicine, and Harvard Medical School. He has been a high volume interventional cardiologist since 2006 and recognized as a Top Doctor in the New York Metro Area by Castle Connolly. Dr. Jeremias has significantly contributed to advancing the field of interventional cardiology and he is considered one of the foremost authorities in coronary physiology and intravascular imaging. He is a co-director of the annual St. Francis Intravascular Imaging and Coronary Physiology Workshop, teaching physicians around the world on “Precision Angioplasty”. Dr. Jeremias is presently engaged in a major global study that could change the path of treating clogged arteries. Known as the ILUMIEN IV trial, this major clinical study is evaluating Optical Coherence Tomography (OCT) to guide coronary stent placement. He is also the principal investigator of DEFINE PCI, an international study on assessing the improvement in blood flow after stent placement for severe coronary blockages.

Dr. Karim Al-Azizi is an Interventional Cardiologist and Structural Heart Disease specialist at Baylor Scott & White Health - The Heart Hospital in Plano, TX. He is the Medical Director of the Cardiac Catheterization Laboratories and the Associate Program Director of the Cardiovascular disease fellowship and a clinical assistant professor at the Texas A and M College of Medicine. His clinical and research interests include complex coronary interventions, ultra-low contrast, physiology and imaging-guided PCI, and transcatheter interventions for valvular heart disease. He speaks at national and international conferences on these subjects and serves as a principal investigator on multiple clinical trials in the field of structural and coronary interventions.

A consultant cardiologist at Mount Sinai Hospital, New York, USA. Features in 13 videos on Wondr Medical. Roxana Mehran generally speaks on Anti-Platelet Drugs , Coronary Optical Coherence Tomography (OCT), Intravascular Ultrasound (IVUS), Cardiovascular Pharmacotherapy, and Cardiac Valves.

Ziad Ali is the Director of the DeMatteis Cardiovascular Institute, Director of Investigational Interventional Cardiology, and Director of Cardio-nephrology at St Francis Hospital & Heart Center in New York. He is also Director of the Angiographic Core Laboratory at Cardiovascular Research Foundation and Associate Professor of Medicine at Columbia University Medical Center. His clinical research interests focus on the use of intravascular imaging and physiology technologies such as optical coherence tomography, intravascular ultrasound, and flow wire assessment to optimize coronary interventions, for which he has served as a Global principal investigator on a number of trials. Dr. Ali is also a recognized innovator, playing an integral role in the development of the Resting Full-Cycle Ratio (RFR) and Shockwave intravascular lithotripsy. Clinically Dr. Ali developed pioneering techniques to perform vascular interventions without contrast administration, including IVUS-guided zero-contrast PCI and OCT using saline flush media, protecting patients with advanced kidney disease from acute kidney injury and the need for dialysis.

Dr. Bruce Samuels is an interventional cardiologist on staff at Cedars-Sinai Medical Center (CSMC) in Los Angeles, California. Dr. Samuels completed his medical studies at Albert Einstein College of Medicine in New York before returning to Southern California to complete his residency and chief residency in Internal Medicine at Harbor-UCLA Medical Center. At CSMC, he trained in both general and interventional cardiology before joining the medical staff there. In addition to his clinical practice in coronary intervention, Dr. Samuels has actively participated in numerous interventional trials including IVUS guided therapy, coronary physiology and microvascular disease. He is also working closely with the Barbra Streisand Women’s Heart Center based at CSMC, working as an interventionalist in the active coronary reactivity research there. As co-chair of a 30-day readmissions task force, he has helped to shape policy for CSMC in its efforts to improve quality delivery of care. He has frequently been invited as faculty to many scientific meetings and is a sought after speaker for numerous peer educational platforms. Dr. Samuels is a fellow of the American College of Cardiology and is Board Certified in Internal Medicine, Cardiovascular Diseases, and Interventional Cardiology. He is married with three sons; his outside interests include contemporary art and long distance running.